

Author index

Volume 279 (1999)

-
- Alhava, E., see Parviainen, M.T. 279, 145
 Argov, Z., see Lev, E.I. 279, 107
 Arnala, I., see Parviainen, M.T. 279, 145
 Ashkenazy, I., see Lev, E.I. 279, 107
- Baba, S., see Kinoshita, M. 279, 15
 Bachmair, F., Huber, Ch., Daxenbichler, G.,
 Quantitation of gene expression by means of
 HPLC analysis of RT-PCR products 279, 25
 Bago, K., see Kinoshita, M. 279, 15
 Bogard, C., see Tchernitchko, D. 279, 133
 Bourrouillou, G., see Vergnes, H. 279, 167
 Brites, F.D., Cavallero, E., de Geitere, C.,
 Nicolaiew, N., Jacotot, B., Rosseneu, M., Fruch-
 art, J.-C., Wikinski, R.L., Castro, G.R., Abnormal
 capacity to induce cholesterol efflux and a new
 LpA-I pre- β particle in type 2 diabetic
 patients 279, 1
 Brühlmann, P., see Krähenbühl, S. 279, 35
- Calapoğlu, M., see Efe, H. 279, 155
 Calvas, P., see Vergnes, H. 279, 167
 Castro, G.R., see Brites, F.D. 279, 1
 Cavallero, E., see Brites, F.D. 279, 1
 Cozzone, P.J., see Torri, G.M. 279, 77
- Daxenbichler, G., see Bachmair, F. 279, 25
 de Geitere, C., see Brites, F.D. 279, 1
 Değer, O., see Efe, H. 279, 155
 Denier, C., see Vergnes, H. 279, 167
 Deybach, J.C., see Tchernitchko, D. 279, 133
- Efe, H., Değer, O., Kirci, D., Karahan, S.C., Örem,
 A., Calapoğlu, M., Decreased neutrophil antiox-
 idative enzyme activities and increased lipid
 peroxidation in hyperlipoproteinemic human
 subjects 279, 155
- Endoh, T., Yagihashi, A., Tanemura, K.,
 Nishinosono, S., Matsukawa, M., Miyao, N.,
 Tsukamoto, T., Watanabe, N., False-negative
 rapid plasma reagin circle card test 279, 179
- Faraggi, D., see Lev, E.I. 279, 107
 Ferré-Masferrer, M., Fuentes-Arderiu, X., Puchal-
 Añé, R., Indirect reference limits estimated from
 patients' results by three mathematical
 procedures 279, 97
 Fruchart, J.-C., see Brites, F.D. 279, 1
 Fuentes-Arderiu, X., see Ferré-Masferrer, M. 279,
 97
- Gouya, L., see Tchernitchko, D. 279, 133
 Grozdea, J., see Vergnes, H. 279, 167
 Gulian, J.-M., see Torri, G.M. 279, 77
- Hadama, T., see Kinoshita, M. 279, 15
 Hiyoshi, S., see Tsuboi, I. 279, 175
 Hoppeler, H., see Krähenbühl, S. 279, 35
 Hoshino, H., see Takahashi, M. 279, 69
 Huber, Ch., see Bachmair, F. 279, 25
- Ida, H., see Tsuboi, I. 279, 175
 Imafuku, Y., see Ozawa, Y. 279, 125
 Inoue, M., see Meshitsuka, S. 279, 47
 Ishihara, Y., see Tatara, T. 279, 117
 Itoh, K., see Utsumi, K. 279, 55
 Iwao, Y., see Tatara, T. 279, 117
- Jääskeläinen, K., see Parviainen, M.T. 279, 145
 Jacotot, B., see Brites, F.D. 279, 1
- Karahan, S.C., see Efe, H. 279, 155
 Kase, R., see Utsumi, K. 279, 55
 Katagiri, Y., see Utsumi, K. 279, 55

- Kinoshita, M., Nakamura, J., Kusaka, H., Hadama, T., Bago, K., Kitajima, M., Baba, S., Automated and simultaneous identification of microsatellite instability by fluorescence-based polymerase chain reaction (PCR) in four loci **279**, 15
- Kirci, D., see Efe, H. **279**, 155
- Kitajima, M., see Kinoshita, M. **279**, 15
- Koeda, T., see Meshitsuka, S. **279**, 47
- Kotani, M., see Utsumi, K. **279**, 55
- Krähenbühl, S., Willer, B., Brühlmann, P., Hoppele, H., Stucki, G., Carnitine homeostasis in patients with rheumatoid arthritis **279**, 35
- Kröger, H., see Parviainen, M.T. **279**, 145
- Kusaka, H., see Kinoshita, M. **279**, 15
- Kushida, K., see Takahashi, M. **279**, 69
- Lamoril, J., see Tchernitchko, D. **279**, 133
- Lev, E.I., Tur-Kaspa, I., Ashkenazy, I., Reiner, A., Faraggi, D., Shemer, J., Argov, Z., Distribution of serum creatine kinase activity in young healthy persons **279**, 107
- Matsukawa, M., see Endoh, T. **279**, 179
- Matsumoto, K., see Ozawa, Y. **279**, 125
- Meshitsuka, S., Inoue, M., Seki, A., Koeda, T., Takeshita, K., Screening of urine by one-dimensional and pulsed-field gradient two-dimensional ¹H NMR spectroscopy: intoxication by propylene glycol in an infant patient **279**, 47
- Miura, Y., see Ozawa, Y. **279**, 125
- Miyao, N., see Endoh, T. **279**, 179
- Mizuoka, K., see Tsuboi, I. **279**, 175
- Nakamura, J., see Kinoshita, M. **279**, 15
- Nakayama, I., see Tsuboi, I. **279**, 175
- Nicolaiew, N., see Brites, F.D. **279**, 1
- Nishi, S., see Ozawa, Y. **279**, 125
- Nishinosono, S., see Endoh, T. **279**, 179
- Nonomiya, T., see Tsuboi, I. **279**, 175
- Nordmann, Y., see Tchernitchko, D. **279**, 133
- Oguchi, T., see Utsumi, K. **279**, 55
- O'Hara, K., see Tsuboi, I. **279**, 175
- Ohkochi, S., see Tataru, T. **279**, 117
- Örem, A., see Efe, H. **279**, 155
- Ozawa, T., see Utsumi, K. **279**, 55
- Ozawa, Y., Sato, S., Matsumoto, K., Nishi, S., Shishido, S., Imafuku, Y., Miura, Y., Yoshida, H., Determination of potassium flux activity of viable human erythrocytes by measuring the release-influx ratio **279**, 125
- Parviainen, M.T., Jäskeläinen, K., Kröger, H., Arnala, I., Alhava, E., Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis **279**, 145
- Puchal-Añé, R., see Ferré-Masferrer, M. **279**, 97
- Puy, H., see Tchernitchko, D. **279**, 133
- Reiner, A., see Lev, E.I. **279**, 107
- Robreau, A.M., see Tchernitchko, D. **279**, 133
- Rosipal, R., see Tchernitchko, D. **279**, 133
- Rosseneu, M., see Brites, F.D. **279**, 1
- Sakuraba, H., see Utsumi, K. **279**, 55
- Sato, S., see Ozawa, Y. **279**, 125
- Sawai, T., see Tsuboi, I. **279**, 175
- Seki, A., see Meshitsuka, S. **279**, 47
- Shemer, J., see Lev, E.I. **279**, 107
- Shigenobu, F., see Tsuboi, I. **279**, 175
- Shimizu, M., see Tsuboi, I. **279**, 175
- Shimmoto, M., see Utsumi, K. **279**, 55
- Shishido, S., see Ozawa, Y. **279**, 125
- Stucki, G., see Krähenbühl, S. **279**, 35
- Takahashi, M., Hoshino, H., Kushida, K., Measurements of urinary nonisomerized form of type I collagen degradation products (α -CTX) in aging, menopause, and osteoporosis with fractures **279**, 69
- Takeda, J., see Tataru, T. **279**, 117
- Takeshita, K., see Meshitsuka, S. **279**, 47
- Tanemura, K., see Endoh, T. **279**, 179
- Taniguchi, K., see Tsuboi, I. **279**, 175
- Tanoue, K., see Utsumi, K. **279**, 55
- Tataru, T., Iwao, Y., Takeda, J., Ishihara, Y., Ohkochi, S., Uedaira, H., Proton nuclear magnetic resonance spectroscopy of urine for rapid multicomponent analysis of intraoperative cellular metabolites **279**, 117
- Tchernitchko, D., Lamoril, J., Puy, H., Robreau, A.M., Bogard, C., Rosipal, R., Gouya, L., Deybach, J.C., Nordmann, Y., Evaluation of mutation screening by heteroduplex analysis in acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis **279**, 133
- Torri, G.M., Torri, J., Gulian, J.-M., Vion-Dury, J., Viout, P., J. Cozzzone, P., Magnetic resonance spectroscopy of serum and acute-phase proteins revisited: a multiparametric statistical analysis of metabolite variations in inflammatory, infectious and miscellaneous diseases **279**, 77
- Torri, J., see Torri, G.M. **279**, 77
- Tsuboi, I., Ida, H., Yoshikawa, E., Hiyoshi, S., Yamaji, E., Nakayama, I., O'Hara, K., Nonomiya, T., Shigenobu, F., Taniguchi, K., Shimizu, M., Sawai, T., Mizuoka, K., Uptake of [³H]-fosfomycin into cells of enterohemorrhagic

- Escherichia coli* O157 and *E. coli* non-O157 279, 175
- Tsukamoto, T., see Endoh, T. 279, 179
- Tur-Kaspa, I., see Lev, E.I. 279, 107
- Uedaira, H., see Tatara, T. 279, 117
- Utsumi, K., Itoh, K., Kase, R., Shimmoto, M., Yamamoto, N., Katagiri, Y., Tanoue, K., Kotani, M., Ozawa, T., Oguchi, T., Sakuraba, H., Urinary excretion of the vitronectin receptor (integrin $\alpha_v\beta_3$) in patients with Fabry disease 279, 55
- Vergnes, H., Grozdea, J., Denier, C., Bourrouillou, G., Calvas, P., Expression of a liver/bone-intestinal hybrid of alkaline phosphatase in neutrophils of Down's syndrome patients 279, 167
- Vion-Dury, J., see Torri, G.M. 279, 77
- Viout, P., see Torri, G.M. 279, 77
- Watanabe, N., see Endoh, T. 279, 179
- Wikinski, R.L., see Brites, F.D. 279, 1
- Willer, B., see Krähenbühl, S. 279, 35
- Yagihashi, A., see Endoh, T. 279, 179
- Yamaji, E., see Tsuboi, I. 279, 175
- Yamamoto, N., see Utsumi, K. 279, 55
- Yoshida, H., see Ozawa, Y. 279, 125
- Yoshikawa, E., see Tsuboi, I. 279, 175



Subject index

Volume 279 (1999)

- Acute phase proteins;** MRS spectroscopy; Serum proteins; Principal component analysis; Inflammation **279, 77**
- Aging;** Human erythrocytes; K^+ flux; Release-influx ratio; Na^+/K^+ -exchanging ATPase **279, 125**
- AIP, acute intermittent porphyria;** PBGD, porphobilinogen deaminase; DDGE, denaturing gradient gel electrophoresis; HA, heteroduplex analysis **279, 133**
- Alcohol;** Creatine kinase; Myoglobin; Physical activity; BMI **279, 107**
- Alkaline phosphatase;** Hybrid isoenzyme; Neutrophils; Down's syndrome **279, 167**
- Antioxidants;** Hyperlipoproteinemia; Antioxidative enzymes; Lipid peroxidation; Neutrophil **279, 155**
- Antioxidative enzymes;** Hyperlipoproteinemia; Antioxidants; Lipid peroxidation; Neutrophil **279, 155**
- Apolipoprotein A-I;** Type 2 diabetes; Postprandial lipemia; Cholesterol efflux; Pre- β -HDL **279, 1**
- Autosequencer;** Microsatellite instability; Replication error; Microsatellite repeats; Loss of heterozygosity **279, 15**
- BMI;** Creatine kinase; Myoglobin; Physical activity; Alcohol **279, 107**
- Bone marker;** Bone resorption; Vertebral fracture; Hip fracture **279, 69**
- Bone resorption;** Bone marker; Vertebral fracture; Hip fracture **279, 69**
- Carnitine;** Rheumatoid arthritis; Muscle strength; Fatty acid metabolism; Carnitine palmitoyltransferase **279, 35**
- Carnitine palmitoyltransferase;** Rheumatoid arthritis; Muscle strength; Fatty acid metabolism; Carnitine **279, 35**
- Cholesterol efflux;** Type 2 diabetes; Postprandial lipemia; Apolipoprotein A-I; Pre- β -HDL **279, 1**
- Creatine kinase;** Myoglobin; Physical activity; BMI; Alcohol **279, 107**
- DDGE, denaturing gradient gel electrophoresis;** AIP, acute intermittent porphyria; PBGD, porphobilinogen deaminase; HA, heteroduplex analysis **279, 133**
- Deoxypyridoline crosslinks;** Fracture; Hormone therapy; N-telopeptide of Type I collagen; Osteoporosis; Postmenopausal women **279, 145**
- Down's syndrome;** Alkaline phosphatase; Hybrid isoenzyme; Neutrophils **279, 167**
- Enterohemorrhagic *Escherichia coli*;** O157; Uptake; Fosfomycin **279, 175**

- Fatty acid metabolism;** Rheumatoid arthritis; Muscle strength; Carnitine; Carnitine palmitoyltransferase **279, 35**
- Fosfomycin;** Enterohemorrhagic *Escherichia coli*; O157; Uptake **279, 175**
- Fracture;** Deoxypyridoline crosslinks; Hormone therapy; N-telopeptide of Type I collagen; Osteoporosis; Postmenopausal women **279, 145**
- Gene expression;** Quantitation; Reverse transcription-polymerase chain reaction; HPLC analysis **279, 25**
- Globotriaosylceramide;** MFabry disease; Vitronectin receptor; Vitronectin **279, 55**
- ¹H NMR;** Propylene glycol; PFG-DQF-COSY; Intoxication; Urine **279, 47**
- HA, heteroduplex analysis;** AIP, acute intermittent porphyria; PBGD, porphobilinogen deaminase; DDGE, denaturing gradient gel electrophoresis **279, 133**
- Hip fracture;** Bone marker; Bone resorption; Vertebral fracture **279, 69**
- Hormone therapy;** Deoxypyridoline crosslinks; Fracture; N-telopeptide of Type I collagen; Osteoporosis; Postmenopausal women **279, 145**
- HPLC analysis;** Quantitation; Gene expression; Reverse transcription-polymerase chain reaction **279, 25**
- Human erythrocytes;** K⁺ flux; Release-influx ratio; Na⁺/K⁺-exchanging ATPase; Aging **279, 125**
- Hybrid isoenzyme;** Alkaline phosphatase; Neutrophils; Down's syndrome **279, 167**
- Hyperlipoproteinemia;** Antioxidative enzymes; Antioxidants; Lipid peroxidation; Neutrophil **279, 155**
- Inflammation;** MRS spectroscopy; Serum proteins; Acute phase proteins; Principal component analysis **279, 77**
- Intoxication;** Propylene glycol; PFG-DQF-COSY; ¹H NMR; Urine **279, 47**
- K⁺ flux;** Human erythrocytes; Release-influx ratio; Na⁺/K⁺-exchanging ATPase; Aging **279, 125**
- Lipid peroxidation;** Hyperlipoproteinemia; Antioxidative enzymes; Antioxidants; Neutrophil **279, 155**
- Loss of heterozygosity;** Microsatellite instability; Replication error; Autosequencer; Microsatellite repeats **279, 15**
- Metabolism;** Nuclear magnetic resonance; Proton; Surgery; Urine **279, 117**
- MFabry disease;** Globotriaosylceramide; Vitronectin receptor; Vitronectin **279, 55**
- Microsatellite instability;** Replication error; Autosequencer; Microsatellite repeats; Loss of heterozygosity **279, 15**
- Microsatellite repeats;** Microsatellite instability; Replication error; Autosequencer; Loss of heterozygosity **279, 15**
- MRS spectroscopy;** Serum proteins; Acute phase proteins; Principal component analysis; Inflammation **279, 77**
- Muscle strength;** Rheumatoid arthritis; Fatty acid metabolism; Carnitine; Carnitine palmitoyltransferase **279, 35**
- Myoglobin;** Creatine kinase; Physical activity; BMI; Alcohol **279, 107**
- N-telopeptide of Type I collagen;** Deoxypyridoline crosslinks; Fracture; Hormone therapy; Osteoporosis; Postmenopausal women **279, 145**
- Na⁺/K⁺-exchanging ATPase;** Human erythrocytes; K⁺ flux; Release-influx ratio; Aging **279, 125**
- Neutrophil;** Hyperlipoproteinemia; Antioxidative enzymes; Antioxidants; Lipid peroxidation **279, 155**
- Neutrophils;** Alkaline phosphatase; Hybrid isoenzyme; Down's syndrome **279, 167**
- Nuclear magnetic resonance;** Metabolism; Proton; Surgery; Urine **279, 117**

- O157**; Enterohemorrhagic *Escherichia coli*; Uptake; Fosfomycin 279, 175
- Osteoporosis**; Deoxypyridoline crosslinks; Fracture; Hormone therapy; N-telopeptide of Type I collagen; Postmenopausal women 279, 145
- Patients' results**; Reference values; Statistical methods 279, 97
- PBGD, porphobilinogen deaminase**; AIP, acute intermittent porphyria; DDGE, denaturing gradient gel electrophoresis; HA, heteroduplex analysis 279, 133
- PFG-DQF-COSY**; Propylene glycol; ^1H NMR; Intoxication; Urine 279, 47
- Physical activity**; Creatine kinase; Myoglobin; BMI; Alcohol 279, 107
- Postmenopausal women**; Deoxypyridoline crosslinks; Fracture; Hormone therapy; N-telopeptide of Type I collagen; Osteoporosis 279, 145
- Postprandial lipemia**; Type 2 diabetes; Cholesterol efflux; Apolipoprotein A-I; Pre- β -HDL 279, 1
- Pre- β -HDL**; Type 2 diabetes; Postprandial lipemia; Cholesterol efflux; Apolipoprotein A-I 279, 1
- Principal component analysis**; MRS spectroscopy; Serum proteins; Acute phase proteins; Inflammation 279, 77
- Propylene glycol**; PFG-DQF-COSY; ^1H NMR; Intoxication; Urine 279, 47
- Proton**; Nuclear magnetic resonance; Metabolism; Surgery; Urine 279, 117
- Quantitation**; Gene expression; Reverse transcription-polymerase chain reaction; HPLC analysis 279, 25
- Rapid plasma reagin (RPR) circle card test**; Syphilis 279, 179
- Reference values**; Statistical methods; Patients' results 279, 97
- Release-influx ratio**; Human erythrocytes; K^+ flux; Na^+/K^+ -exchanging ATPase; Aging 279, 125
- Replication error**; Microsatellite instability; Autosequencer; Microsatellite repeats; Loss of heterozygosity 279, 15
- Reverse transcription-polymerase chain reaction**; Quantitation; Gene expression; HPLC analysis 279, 25
- Rheumatoid arthritis**; Muscle strength; Fatty acid metabolism; Carnitine; Carnitine palmitoyltransferase 279, 35
- Serum proteins**; MRS spectroscopy; Acute phase proteins; Principal component analysis; Inflammation 279, 77
- Statistical methods**; Reference values; Patients' results 279, 97
- Surgery**; Nuclear magnetic resonance; Metabolism; Proton; Urine 279, 117
- Syphilis**; Rapid plasma reagin (RPR) circle card test 279, 179
- Type 2 diabetes**; Postprandial lipemia; Cholesterol efflux; Apolipoprotein A-I; Pre- β -HDL 279, 1
- Uptake**; Enterohemorrhagic *Escherichia coli*; O157; Fosfomycin 279, 175
- Urine**; Nuclear magnetic resonance; Metabolism; Proton; Surgery 279, 117
- Urine**; Propylene glycol; PFG-DQF-COSY; ^1H NMR; Intoxication 279, 47
- Vertebral fracture**; Bone marker; Bone resorption; Hip fracture 279, 69
- Vitronectin receptor**; MFabry disease; Globotriaosylceramide; Vitronectin 279, 55
- Vitronectin**; MFabry disease; Globotriaosylceramide; Vitronectin receptor 279, 55